Testosterone for Low Desire in Women

The short version

If desire has genuinely gone and you have raised it with a clinician, you may have been told there is nothing to offer. That is not quite true, and it is also not as open a door as the internet suggests.

There is a clinical practice guideline for using testosterone to treat low desire in women, published by the International Society for the Study of Women's Sexual Health¹. It is a real, specific, evidence-reviewed pathway. It is also much narrower than the advertising around it, and one of its clearest instructions is the one most often reversed.

Three things to carry into an appointment:

• It is scoped to postmenopausal women with hypoactive sexual desire disorder. Limited data extend it to late reproductive age.
• A blood test cannot diagnose you. The guideline says so explicitly.
• The benefit is described as moderate, and long-term safety has not been established.

Scope, so you land in the right place. Whether a GLP-1 changed your desire at all is a separate question with a much weaker evidence base — that is on GLP-1s and sex drive. This page is about what can be offered if the desire is genuinely gone, whatever caused it.

Who the guideline is actually for

The Global Consensus Position Statement on the Use of Testosterone Therapy for Women endorses it for postmenopausal women with hypoactive sexual desire disorder — and only for them¹.

The ISSWSH guideline, built on top of that statement by a multidisciplinary expert panel using a modified Delphi consensus, adds one extension: limited data also support use in late reproductive age premenopausal women.

It also draws a line that matters more than the age one. Testosterone is recommended for HSDD that is not primarily related to modifiable factors or comorbidities — the guideline names relationship problems and mental health among them. That is not a brush-off. It is the recognition that a hormone will not fix a situation, and that treating the situation is the better medicine when the situation is the cause.

So the honest filter before you ask about it:

• Are you postmenopausal, or close to it?
• Is the loss of desire distressing to you, rather than to someone else?
• Is there an obvious modifiable cause — an antidepressant, exhaustion, an unhappy relationship, untreated pain with sex — that has not been addressed?

That last one is worth taking seriously rather than resenting. If sex hurts, desire falls for an excellent reason, and the treatment is for the pain.

The instruction almost everyone gets backwards

Here is the sentence to bring with you: a total testosterone level should not be used to diagnose hypoactive sexual desire disorder¹.

That runs directly against the most common version of this conversation, in which a woman is told to "get her levels checked" to see whether low testosterone explains her libido. The guideline does not support that, for a straightforward reason — the assays are not reliable at the concentrations found in women, and desire does not track a number.

The diagnosis is clinical. It comes from a biopsychosocial assessment, which is the framework the guideline is built on. Bloodwork has a role, but it is monitoring — checking that treatment has not pushed you above the physiologic female range — not qualification.

If you are told your levels are "normal so it can't be that", that is not what the guideline says either. The number was never the test.

What treatment actually looks like

Systemic transdermal testosterone is what the guideline recommends — through the skin, at a dose intended to keep you inside the normal female physiologic range.

Three things it asks of the clinician, which tell you what a good conversation sounds like:

Informed consent before starting. Not a formality here.

An explicit discussion that this is off-label. The guideline names shared decision-making and a comprehensive discussion of off-label use along with benefits and risks. If nobody mentions the words "off-label", the conversation is incomplete.

Monitoring and follow-up, which is where testosterone levels genuinely belong.

How well it works, stated the way the guideline states it

"Current available research supports a moderate therapeutic benefit."

That is the guideline's own phrase, and it is worth not upgrading. Moderate is a real effect — meaningfully better than nothing, for the right patient — and it is not the transformation the marketing around testosterone tends to promise.

On safety: physiologic testosterone use showed no serious adverse events, but long-term safety has not been established. Both halves are load-bearing. The reassurance is genuine and it is bounded by how long anyone has looked.

And the GLP-1 question

Nothing has studied testosterone therapy for desire in women taking a GLP-1. Not for benefit, not for interaction, not for whether the two questions are even related.

What that means practically is that these are two separate conversations that happen to arrive at the same appointment. If your desire fell away and you also started an injection, the honest position is that the drug's role is unsettled — and that if you meet the guideline's criteria, the testosterone pathway exists on its own terms regardless of what the GLP-1 did or did not do.

Where this sits on the evidence scale

Testosterone helps hypoactive sexual desire disorder in postmenopausal women: moderate, and guideline-endorsed. A clinical practice guideline from a multidisciplinary expert panel, built on an international consensus position statement, describing a moderate therapeutic benefit.

It helps premenopausal women: limited. The guideline extends to late reproductive age on limited data, and the global position statement does not endorse it there at all.

A testosterone blood level identifies who will benefit: contradicted. The guideline states a total testosterone level should not be used to diagnose the condition.

Long-term safety: not established. No serious adverse events at physiologic doses, over the durations studied.

Any relationship to GLP-1 use: unstudied. No evidence in either direction, and this page will not invent one.